Nanosynergist-engineered oncolytic adenovirus enhancing immune-virotherapy efficacy for glioblastoma via interrupting antiviral responses
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Virus-based gene therapy research · CAR-T cell therapy research · Viral Infectious Diseases and Gene Expression in Insects
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (75)
Show source-provided references
1. Progress in glioma diagnosis, classification and treatment10.1038/nrneurol.2015.242 ↗
2. Glioma
3. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 200410.1093/neuonc/noq030 ↗
4. Brain tumors10.1056/NEJM200101113440207 ↗
5. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma10.1056/NEJMoa043330 ↗
6. Glioma targeted therapy: insight into future of molecular approaches10.1186/s12943-022-01513-z ↗
7. Immunotherapy for glioma: current management and future application10.1016/j.canlet.2020.02.002 ↗
8. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma10.1200/JCO.2014.58.3377 ↗
9. China approves world's first oncolytic virus therapy for cancer treatment10.1093/jnci/djj111 ↗
10. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant Glioma10.1200/JCO.2017.75.8219 ↗
11. A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma10.1038/s41467-022-31262-y ↗
12. Oncolytic Herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing10.1073/pnas.101136398 ↗
13. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes10.1016/0092-8674(94)90215-1 ↗
14. Integrating oncolytic viruses in combination cancer immunotherapy10.1038/s41577-018-0014-6 ↗
15. Oncolytic viruses: a new class of immunotherapy drugs10.1038/nrd4663 ↗
16. Recent progress in the battle between oncolytic viruses and tumours10.1038/nrc1750 ↗
17. Optimizing oncolytic virotherapy in cancer treatment, Nature reviews10.1038/s41573-019-0029-0 ↗
18. Oncolytic viruses10.1038/nrc948 ↗
19. Oncolytic viruses in cancer treatment: a review10.1001/jamaoncol.2016.2064 ↗
20. Oncolytic virus-based hepatocellular carcinoma treatment: current status, intravenous delivery strategies, and emerging combination therapeutic solutions
21. Expression of the adenovirus receptor and its interaction with the Fiber Knob10.1006/excr.1999.4761 ↗
22. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 510.1126/science.275.5304.1320 ↗
23. PED/PEA-15 modulates Coxsackievirus–Adenovirus receptor expression and adenoviral infectivity via ERK-mediated signals in glioma cells10.1089/hum.2009.181 ↗
24. Effective high-capacity gutless adenoviral vectors mediate transgene expression in human Glioma cells10.1016/j.ymthe.2006.05.006 ↗
25. Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy10.3171/jns.2005.103.6.1058 ↗
26. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways10.1517/14712590903170653 ↗
27. Directed natural evolution generates a next-generation oncolytic virus with a high potency and safety profile
28. Therapy with oncolytic viruses: progress and challenges10.1038/s41571-022-00719-w ↗
29. Oncolytic virotherapy: basic principles, recent advances and future directions10.1038/s41392-023-01407-6 ↗
30. The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis10.1128/JVI.01921-08 ↗
31. Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy10.1016/j.ymthe.2018.01.019 ↗
32. Synergistic interaction between oncolytic viruses augments tumor killing10.1038/mt.2010.44 ↗
33. What does Stat3 do?10.1172/JCI0215650 ↗
34. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway10.1016/0092-8674(94)90235-6 ↗
35. Stat3: a STAT family member activated by Tyrosine phosphorylation in response to epidermal growth factor and interleukin-610.1126/science.8140422 ↗
36. STAT3 complements defects in an interferon-resistant cell line: evidence for an essential role for STAT3 in interferon signaling and biological activities10.1073/pnas.95.10.5568 ↗
37. A novel anti-viral role for STAT3 in IFN-α signalling responses10.1007/s00018-016-2435-3 ↗
38. STATs and gene regulation10.1126/science.277.5332.1630 ↗
39. STAT3 as an Adapter to couple phosphatidylinositol 3-Kinase to the IFNAR1 chain of the Type I interferon receptor10.1126/science.276.5317.1418 ↗
40. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway10.1128/JVI.73.10.8469-8475.1999 ↗
41. STAT3 Ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling10.1128/JVI.77.11.6385-6393.2003 ↗
42. Stat proteins and oncogenesis10.1172/JCI0215617 ↗
43. Activation of STAT3 is a key event in TLR4 signaling-mediated melanoma progression10.1038/s41419-020-2440-1 ↗
44. miR-204 inhibits angiogenesis and promotes sensitivity to cetuximab in head and neck squamous cell carcinoma cells by blocking JAK2-STAT3 signaling10.1016/j.biopha.2018.01.055 ↗
45. STAT3: a promising therapeutic target in multiple myeloma10.3390/cancers11050731 ↗
46. Constitutive activation of Stat3 signaling confers resistance to Apoptosis in human U266 myeloma cells10.1016/S1074-7613(00)80011-4 ↗
47. Unabated adenovirus replication following activation of the cGAS/STING-dependent antiviral response in human cells10.1128/JVI.02608-14 ↗
48. α-Interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequences10.1038/314637a0 ↗
49. Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression10.1016/j.biomaterials.2014.03.060 ↗
50. Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model10.1016/j.jconrel.2016.02.046 ↗
51. Self-assembly of amphiphilic phospholipid peptide dendrimer-based nanovectors for effective delivery of siRNA therapeutics in prostate cancer therapy10.1016/j.jconrel.2020.04.003 ↗
52. Assembling structurally customizable synthetic carriers of siRNA through thermodynamically self-regulated process
53. PAMAM dendrimers as promising nanocarriers for RNAi therapeutics10.1016/j.mattod.2015.06.003 ↗
54. Polymeric siRNA gene delivery – transfection efficiency versus cytotoxicity10.1016/j.jconrel.2019.10.046 ↗
55. Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment
56. E. Fröhlich, The rOle of Surface Charge in Cellular Uptake and Cytotoxicity of Medical Nanoparticles, Int. J. Nanomed., 5577. http://10.2147/IJN.S36111.10.2147/IJN.S36111 ↗
57. Surface charge-dependent cytotoxicity of plastic nanoparticles in alveolar cells under cyclic stretches10.1021/acs.nanolett.0c02463 ↗
58. Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression10.1016/j.biomaterials.2014.03.060 ↗
59. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis10.1016/j.jconrel.2015.01.005 ↗
60. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy10.1038/80474 ↗
61. Functional domains of adenovirus type 5 E1a proteins10.1016/0092-8674(87)90175-9 ↗
62. A novel anti-viral role for STAT3 in IFN-α signalling responses10.1007/s00018-016-2435-3 ↗
63. A novel polyethyleneimine-decorated FeOOH nanoparticle for efficient siRNA delivery10.1016/j.cclet.2020.11.024 ↗
64. A Lysosome-activated tetrahedral nanobox for encapsulated siRNA delivery
65. Biology of adenovirus and its use as a vector for gene therapy10.1089/hum.2004.15.1022 ↗
66. Dynamic competition for hexon binding between core protein VII and lytic protein VI promotes adenovirus maturation and entry10.1073/pnas.1920896117 ↗
67. Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles10.1002/wnan.1452 ↗
68. Carriers break barriers in drug delivery: endocytosis and endosomal escape of gene delivery vectors10.1021/acs.accounts.9b00177 ↗
69. Adenovirus entry: from infection to immunity10.1146/annurev-virology-092818-015550 ↗
70. Dynamic competition for hexon binding between core protein VII and lytic protein VI promotes adenovirus maturation and entry10.1073/pnas.1920896117 ↗
71. Oncolytic virotherapy as immunotherapy10.1126/science.abk3436 ↗
72. Dendritic cells and the control of immunity10.1038/32588 ↗
73. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy10.1016/j.cell.2017.08.027 ↗
74. Studies on the mechanism of replication of adenovirus DNA II. The nature of single-stranded DNA in replicative intermediates10.1128/jvi.12.5.1131-1138.1973 ↗
75. A recombinant Newcastle disease virus expressing MMP8 promotes oncolytic efficacy10.1016/j.cclet.2021.05.001 ↗